Digital Twin-Enabled Personalized Nutrition Improves Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes: Results of a 1-Year Randomized Controlled Study
Authors' conclusion
At 1 year, DT-enabled personalized treatment significantly improved hyperglycemia and surrogate markers of MAFLD and MRI-PDFF.
Study context
- Population
- People with T2Drandomized 2:1
- Participants
- 319 people
- Comparison
- Digital twin (DT)-enabled personalized nutrition, activity and sleep vs standard care
- Primary endpoint
- Change in HbA1c and medicine reduction, DT vs SC
- Follow-up
- 1 year
Methodological detailsopen-label, randomized 2:1
- Open-label
- Randomized 2:1
Primary result
As reported in the abstract
Change in HbA1c
DT
−2.9
SD 1.8
Standard care (SC)
−0.3
SD 1.2
P < 0.001
- Remission of T2D with DT
- 72.7%
Secondary outcomes
| Outcome | DT | SC | P value |
|---|---|---|---|
| Change in NAFLD liver fat score, patients with abnormal baseline values · baseline to 1 yearMean | −2.5 (SD 2.0) | −0.1 (SD 1.5) | P < 0.001 |
| Change in NAFLD fibrosis score, patients with abnormal baseline values · baseline to 1 year | −1.20 (SD 0.9) | −0.1 (SD 1.0) | P < 0.001 |
Other liver fat and fibrosis scores and %liver fat by MRI-PDFF
- Improvements seen with DT compared with SC in other liver fat, fibrosis score, and %liver fat by MRI-PDFF
Original publication
Digital Twin-Enabled Personalized Nutrition Improves Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes: Results of a 1-Year Randomized Controlled Study. Endocr Pract. Published 29 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →